Page 8 - Astrazeneca

Astra's Covid-19 vaccine found safe for pregnancy, fertility in study

The rate of miscarriage was roughly the same between the vaccine and placebo groups

WHO chief, Mandaviya talk Covaxin, resuming Covishield supply to COVAX

WHO chief Tedros Adhanom Ghebreyesus discussed the issue of the emergency use listing of Bharat Biotech's COVID-19 vaccine Covaxin and resumption of supplies of the Serum Institute of India-manufactured AstraZeneca vaccine to the COVAX facility among other topics during a telephonic conversation with Health Minister Mansukh Mandaviya. Had a call with @mansukhmandviya, India's Health Minister, to discuss #India's ongoing #COVID19 vaccination programme; the need for a global pandemic agreement; digital health; & traditional medicine. We welcome India's support to strengthen WHO, incl. via flexible, sustainable financing, Ghebreyesus tweeted on Tuesday. The WHO Director-General said that he also discussed with Mandaviya vaccine equity issues: the resumption of SII/AstraZeneca vaccine supplies to #COVAX; the Covaxin Emergency Use Listing process; and technology and license sharing through C-TAP. COVID-19 Technology Access Pool (C-TAP) was launched in May last year for facilitating ...

AstraZeneca sets up clinical data and insights division in India

Drug firm AstraZeneca on Wednesday said it has launched a clinical data and insights division in India for data-related management of its clinical trials. The Bengaluru-based clinical data and insights (CDI) division is a critical advancement to support a growing global portfolio and build on internal data expertise, the drug firm said in a statement. The CDI division works across therapy areas and portfolios, supporting early and late-stage clinical programmes from Phase 1 to Phase 3, with an integrated end-to-end approach for clinical data, analytics, insights and risk management, it added. Currently, a 30-member team, the division is expected to grow to over 100 members by 2022, the drug firm said. "India has seen a constant uptick in investment in areas such as business services, engineering, digital, IT, R&D and product development from global Fortune-500 companies. AstraZeneca in India is no different since its inception, AstraZeneca India has supported the global ...

A step from Covid-19 pills as Merck & Co seeks FDA approval

An application was submitted with the Food and Drug Administration for molnupiravir to treat mild-to-moderate Covid-19 in adults at risk of developing a severe illness that may require hospitalization

AstraZeneca antibody drug effective at treating mild Covid-19 in trial

The cocktail halved the risk of developing severe illness or death compared with a placebo in participants who had been symptomatic for a week or less and weren't hospitalized, Astra said.

Australia drugs regulator approves India-made AstraZeneca vaccine for Covid

China-made vaccine recognised as well as Australia starts to unwind some of the world's most intense pandemic border restrictions.

AstraZeneca to seek US approval for Covid-19 vaccine later this year

The pharmaceutical company AstraZeneca will file a request for approval of its novel coronavirus vaccine in the US later this year, the company said in a statement

New AstraZeneca tie-up to explore vaccine tech for cancer, heart disease

An Imperial College London start-up has tied up with British-Swedish biopharmaceutical major AstraZeneca to explore the therapeutic uses of its vaccine technology

AstraZeneca Pharma India gets nod to import, market Selumetinib capsules

Drug firm AstraZeneca Pharma India on Sunday said it has received import and market permission from the Indian drug regulator for Selumetinib capsules. The company has received the import and market permission in Form CT-20 from the Drugs Controller General of India for Selumetinib 10 mg & 25 mg capsules, AstraZeneca Pharma India said in a regulatory filing. The receipt of this permission paves way for the launch of Selumetinib 10 mg & 25 mg capsules in India, subject to the receipt of related statutory approvals and licenses, it added. Selumetinib 10 mg & 25 mg capsules are indicated for treatment of pediatric patients 3 years of age and older with neurofibromatosis type 1 and who have symptomatic, inoperable plexiform neurofibromas, it added.

Covid-19 vaccine: AstraZeneca to develop Imperial's new RNA technology

Under the deal, VaxEquity, a start-up founded by Imperial vaccinologist Robin Shattock, could receive up to $195 million if certain milestones are met

Not many places left for Covid to evade immunity: UK vaccine creator

There aren't many places left for the COVID-19 virus to mutate and evade immunity as it will only get weaker with time, said the creator of the Oxford-AstraZeneca vaccine

India may allow smaller gap between Covishield doses sold privately: Report

Private hospitals and clinics will give their paying patients the option to receive their second dose of the vaccine 4 weeks after the first, down from between 12 and 16 weeks currently, say sources

Serum Institute to invest $68 mn in UK vaccine-maker Oxford Biomedica

British cell therapy firm makes announcement.

EU says people vaccinated with AstraZeneca should be able to travel to US

The EU has its own safe-travel list, from which the United States was recently removed after a spike in infections there.

UK approves Pfizer, AstraZeneca vaccines as booster doses for Covid-19

The UK's health regulator has approved Pfizer and AstraZeneca vaccines for booster doses against Covid-19, even as the country's decision on the third dose remains pending.

Astrazeneca and European Union strike deal to end vaccine supply dispute

The deal ends a blame game over the EU's slow start in vaccinating its 448 million population

Better than booster shots, non-vaccines promise to build Covid immunity

Monoclonal antibodies boost immune response to infections by binding to particular sites on the spike protein of the virus that causes Covid-19.

No plan yet to revise Covishield 84-day dose gap, clarifies govt

Earlier there were reports that government could make a move to reduce the minimum gap between two doses of the Covishield Covid-19 vaccine, but NTAGI has denied the reports

SII informs Centre it will supply around 200 mn Covishield doses in Sep

SII has informed the Centre that it will be able to supply around 20 crore doses of COVID-19 vaccine Covishield in September itself to Government to India and private hospitals, official sources said

India to resume Covid vaccine exports in 2022: Head of govt expert panel

A second wave of Covil infections and local supply delays prompted the government to prioritize its own citizens and halted overseas shipments of vaccines in April.